Literature DB >> 9112461

Preoperative radiotherapy (RT) for rectal cancer: predictive factors of tumor downstaging and residual tumor cell density (RTCD): prognostic implications.

C Berger1, A de Muret, P Garaud, S Chapet, P Bourlier, A Reynaud-Bougnoux, E Dorval, L de Calan, N Huten, O le Folch, G Calais.   

Abstract

PURPOSE: To determine predictive factors and prognostic value of tumor downstaging and tumor sterilization after preoperative RT for rectal cancer. METHODS AND MATERIALS: Between 1977 and 1994, 167 patients with a histologically proven adenocarcinoma (70 T2, 65 T3, 29 T4, and 3 local recurrences) underwent preoperative RT. Median dose was 44 Gy (5-73 Gy). Surgery was performed in a mean time of 5 weeks after RT. Pathologic specimens have been reviewed by the same pathologist in order to specify the modified Astler Coller classification (MAC), and to quantify the residual tumor cell density (RTCD).
RESULTS: According to the MAC, there was 9 stage 0 (5%), 10 stage A (6%), 103 stage B1-B3 (62%), and 45 stage C1-C3 (27%) tumors. Seventeen percent and 56% of the patients who received a dose > or = 44 Gy had respectively a 0-A and a B tumor, compared to 4 and 69% in those who received a dose < 44 Gy (p = 0.04). Tumor differentiation and a longer interval before surgery were significantly associated with a more frequent downstaging, and preoperative staging correlated well to the postoperative pathological findings. According to the RTCD, 62 tumors (37%) showed no or only rare foci of residual tumor cells (Group 1); 62 (37%) showed an intermediate RTCD (Group 2); and 43 (26%) a high RTCD (Group 3). No predictive factor of RTCD was statistically significant. In univariate analysis, postoperative staging was a significant prognostic factor, with corresponding 5-year overall survival rates in 0-A, B, and C stages of 92, 67, and 26% (p < 0.01). RTCD was not a prognostic factor. However, overall and disease-free survival rates for patients with complete pathologic response of 83% at 2 and 5 years suggested a better outcome in this subgroup of patients.
CONCLUSION: The favorable influence of higher doses of preoperative RT on pathologic stage has been observed. Tumor differentiation, preoperative classification and time before surgery were the other predictive factors of tumor downstaging. However, there was no predictive factor of complete pathologic response. Even after preoperative RT, postoperative staging remained a prognostic factor.

Entities:  

Mesh:

Year:  1997        PMID: 9112461     DOI: 10.1016/s0360-3016(96)00577-9

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  29 in total

1.  Possible predictors of histopathological response to neoadjuvant chemoradiotherapy for rectal cancer.

Authors:  Robert Farkas; Eva Pozsgai; Andrew V Schally; Andras Szigeti; Edit Szigeti; Zoltan Laszlo; Andras Papp; Eva Gomori; Laszlo Mangel; Peter O Horvath; Szabolcs Bellyei
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-08       Impact factor: 4.553

2.  Usefulness of two independent histopathological classifications of tumor regression in patients with rectal cancer submitted to hyperfractionated pre-operative radiotherapy.

Authors:  Lukasz Liszka; Ewa Zielińska-Pajak; Jacek Pajak; Dariusz Gołka; Jacek Starzewski; Zbigniew Lorenc
Journal:  World J Gastroenterol       Date:  2007-01-28       Impact factor: 5.742

Review 3.  Non-operative management of rectal cancer: understanding tumor biology.

Authors:  Iris H Wei; Julio Garcia-Aguilar
Journal:  Minerva Chir       Date:  2018-05-24       Impact factor: 1.000

4.  Predictive markers of chemoradiotherapy for rectal cancer: comparison of biopsy specimens taken before and about 1 week after the start of chemoradiotherapy.

Authors:  Toshiyuki Suzuki; Sotaro Sadahiro; Akira Tanaka; Kazutake Okada; Gota Saito; Akemi Kamijo; Takeshi Akiba; Shuichi Kawada
Journal:  Int J Clin Oncol       Date:  2015-04-02       Impact factor: 3.402

5.  Preoperative radiochemotherapy and sphincter-saving resection for T3 carcinomas of the lower third of the rectum.

Authors:  E Rullier; B Goffre; C Bonnel; F Zerbib; M Caudry; J Saric
Journal:  Ann Surg       Date:  2001-11       Impact factor: 12.969

Review 6.  Rectal cancer treatment: improving the picture.

Authors:  Juan A Diaz-Gonzalez; Leire Arbea; Javier Aristu
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

7.  Pathologic response to neoadjuvant treatment in locally advanced rectal cancer and impact on outcome.

Authors:  Mahshid Jalilian; Sidney Davis; Mohammadreza Mohebbi; Bhuvana Sugamaran; Ian W Porter; Stephen Bell; Satish K Warrier; Roger Wale
Journal:  J Gastrointest Oncol       Date:  2016-08

8.  Instrumental clinical restaging, pathological evaluation, and tumor regression grading: how to assess the response to neoadjuvant chemoradiotherapy for rectal cancer.

Authors:  Enrico Benzoni; Giovanni Terrosu; Donatella Intersimone; Elisa Milan; Germana Chiaulon; Vittorio Bresadola; Cosimo Sacco; Elisa Sattin; Fabrizio Bresadola; Claudio Avellini
Journal:  Int J Colorectal Dis       Date:  2006-03-15       Impact factor: 2.571

9.  Clinical significance of tumor regression grade in rectal cancer with preoperative chemoradiotherapy.

Authors:  Young Joo Park; Byung Ryul Oh; Sang Woo Lim; Jung Wook Huh; Jae Kyun Joo; Young Jin Kim; Hyeong Rok Kim
Journal:  J Korean Soc Coloproctol       Date:  2010-08-31

10.  Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy.

Authors:  Leyo Ruo; Satish Tickoo; David S Klimstra; Bruce D Minsky; Leonard Saltz; Madhu Mazumdar; Philip B Paty; W Douglas Wong; Steven M Larson; Alfred M Cohen; Jose G Guillem
Journal:  Ann Surg       Date:  2002-07       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.